Report: Prescription Drugs: Global Outlook to 2008 TOC

1.Disease Demographics and the Rx Drug Market

Pharmaceutical Planning and Disease Statistics
The Scale of Major Disease Populations
Health Risks and Death Linked to `Modern Lifestyle

2.Leading Rx Drugs, Revenues and Drug Companies

The Leading Twenty Prescription Drugs
Leading Twenty Rx Drugs by Disease Categories
Leading Twenty Rx Drugs by Top Pharma Companies
The Best Selling 276 Prescription Drugs
The Best Selling Drugs by Disease Categories

3.Drug Market Distribution, Price and Cost Arrangement

Approaches to Regional Price Setting
A Case Study of a Drug Distribution Channel
Distribution Supply Chain and Distributors
Example of How Rx Drugs Reach Patients (HMO)

4.Pharma Partnering and M&A Trends

Review of Pharmaceutical Partnerships
Comparing Alliances and M&As
Key Findings About Alliances and M&As
Background to the Following Data Tables

5.Patent Expiries and New Drug Pipelines

The Impact of Nearing Patent Expirations
Late Stage Drug Pipeline in 2003

6.Navigating World Drug Regulatory Organizations Drug

R&D and Regulatory Approval Processes
Drug Approvals in the USA (North America)
Overview of the Drug Approval Process in the
USA (FDA)
Drug Approvals in the European Union (EU)
Overview of the Drug Approval Process in the
European Union
`Mutual Recognition Principle
The Centralized Approval Procedure
Decentralized Approval Procedure
Drug Approvals in Japan
Overview of the Drug Approval Process in Japan
Applications for Approval of Drugs Manufactured
Outside of Japan
Japans Priority Review System
The Orphan Drug Designation
Regional Drug Regulatory Issues to Consider
USA (North America)
The European Union
In Japan

7.The Global Rx Drug Market Size and Outlook to 2008

Rx Drug Market Size of the Developed World
- Selected Top 276) Global Rx Drug Market Size by
- Disease and Revenues
- Top Six Market Segments and Subsegments

8.Conclusions and Issues to Consider

Drug Companies Use Disease Demographics
Epidemiology Based Pharmaceutical Planning Large
Disease Populations Point to Potential Marketing
Opportunities
Health Risk Factors Lead to Sickness & Death
Key Points about Global Regulators and Issues
Need for Government Drug Regulatory Approval
International Drug R&D and Approval Processes
Regulatory Trends
Drug Patent Expiration Dates and New Drug
Pipeline Patent Expirations Looming to
Cause Big Losses Current Drug R&D
Pipeline is Weak
Drug Pricing & Distribution Arrangements
Pricing Arrangements
Drug Distribution Supply Chain
Pharma Alliances and M&As
Alliance Trends
Rx Drug Market Size
Best Selling Rx Drugs
Issues to Consider

9.Appendix

Pharmaceutical Business Glossary
Contacts to the Top 55 Pharma Companies
Links to Worldwide Drug Regulatory Organizations

List of Tables

Table 1. Major Disease Populations by Annual New Patients
Table 2. Major Disease Populations by Total Existing Patients
Table 3. Disease Populations in the Developed World
Table 4. Major Health Risk Factors Leading to Death
Table 5. Leading 20 Rx Drugs Global Sales ($M)
Table 6. Leading 15 Disease Categories by Global Sales
Table 7. Disease Category Definitions Used in this Section
Table 8. Rx Drugs by Disease Indication and Global Sales
Table 9. Rx Drug Pricing Tiers and Channels by Region
Table 9. Rx Drug Pricing Tiers and Channels by Region
Table 10. Model of US Pricing for Brand Name Rx Drugs
Table 11. Top Level of US Wholesale Rx Drug Distribution Channel
Table 12. Details of the US Retail Pharmacy Channel
Table 13. Key Rx Drug Distributors by International Region
Table 14. Map of Pharma Alliances and M&As
Table 15. Pharma Strategic Alliances and M&As by MajorDisease
Table 16. Alliances and M&As, 2003
Table 17. Alliances and M&As, 2002
Table 18. Alliances and M&As, 2001
Table 19. Alliances and M&As, 2000
Table 20. Summary of Drug Patent Expirations and Lost Revenues
Table 21. Drug Patent Expirations to 2008
Table 22. Drug Patent Expirations by Disease Category and Indication
Table 23. Drug Pipeline by Clinical Phase in 2003
Table 24. Drug Pipeline Summary by Disease for 2003
Table 25. Late Stage Rx Drug Development Pipeline (2003)
Table 26. Relationship of Drug Regulation to Drug Development
Table 27. Total Audited World Rx Drug Sales by Regions, 2002
Table 28. Estimated Global Rx Drug Sales by Regions, 2002 - 2008
Table 29. Top 10 Products in 2002 Global Rx Drug Sales
Table 30. Top 276 Human Rx Drug Global Market Size Sorted by 2003 Revenues ($M) and Disease Segments (Summary), 2002-2008E
Table 31. Top 276 Human Rx Drug Global Market Size Sorted by CAGR and Disease Segments (Summary), 2002-2008E
Table 32. Top 276 Human Rx Drug Global Market Size by Disease (Detail) ($M) 2002-2008E

List of Illustrations

Figure 1. An Rx Drug Distribution Arrangement
Figure 2. Map of Strategic Alliances and M&As
Figure 3. Selected M&As by Valuation ($M)
Figure 4. Pharma Strategic Alliances and M&As by Major Disease
Figure 5. Navigating the Drug R&D and Approval Process
Figure 6. The US FDA New Drug Approval Process Flowchart
Figure 7. EU Centralized Drug Approval Procedure Flowchart
Figure 8. EU Decentralized New Drug Approval Procedure Flowchart
Figure 9. Japan MHLW New Drug Approval Flowchart
Figure 10. Estimated Selected (Top 276) Human Rx Drug Global Market Size by Revenues ($M) and Disease Segments, 2002-2008E
Figure 11. Comparison of Disease Segment Market Shares for the Selected (Top 276) Global Human Rx Drug Market, 2002 and 2008
Figure 12. Market Size by the Estimated `Cardiovascular Segment Revenues, 2002-2008
Figure 13. Market Size by Estimated `CNS Subsegment Revenues, 2002-2008
Figure 14. Market Size by Estimated `Infections Subsegment Revenues, 2002-2008
Figure 15. Market Size by Estimated `Respiratory & Allergy Subsegment Revenues, 2002-2008
Figure 16. Market Size by the Estimated `GastrointestinalSubsegment Revenues, 2002-2008
Figure 17. Market Size by the Estimated `Cancer Subsegment Revenues, 2002-2008

Prescription Drugs: Global Outlook to 2008

Table of Contents